Drug cost-sharing schemes are flawed and costly, says BOPA

摘要

Schemes developed by the pharmaceutical industry to make expensive new cancer drugs available through the NHS are flawed, labour intensive and costly, according to an investigation by oncology pharmacists. Patient access schemes (PASs) have been designed by drug companies to allow access to treatments that may not otherwise have been deemed cost-effective for the NHS. The idea behind a PAS is that the drug company shares the cost of the drug with the NHS either by offering the treatment at a discount or generating a refund on full-cost.